Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept
Background: Few studies exist that evaluate the therapeutic response among switchers of tumor necrosis antagonists in patients with psoriasis, especially Asian patients. Objective: This study aimed to evaluate the safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis w...
Saved in:
Main Authors: | Ting-Shun Wang (Author), Tsen-Fang Tsai (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2013-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Treatment response in patients with moderate-to-severe psoriasis who had inadequate response to prior secukinumab
by: Tai-Siang Chiu, et al.
Published: (2019) -
Practical experience of ustekinumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to previous tumor necrosis factor blockers
by: Tzu-Chang Wang, et al.
Published: (2015) -
Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience
by: Ting-Shun Wang, et al.
Published: (2017) -
A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy
by: Giorgio L Colombo, et al.
Published: (2009) -
Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice
by: L.S. van der Schoot, et al.
Published: (2023)